🏆 Deal of the Month · April 2024
Neurosterix raised USD 63 million in a Series A round; the company's valuation was not disclosed. The round was backed by Perceptive Life Sciences, Perceptive Advisors, and Acorn Bioventures. This financing was recognised as Venionaire DealMatrix Deal of the Month for April 2024.
Neurosterix — key deal facts
| Company | Neurosterix |
| Founded | 2024 |
| Headquarters | Geneva, Switzerland |
| Amount raised | USD 63M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | Perceptive Life Sciences Perceptive Advisors Acorn Bioventures |
Who invested in Neurosterix?
The round was funded by Perceptive Life Sciences, Perceptive Advisors, and Acorn Bioventures. The presence of both Perceptive Life Sciences and Perceptive Advisors reflects coordinated commitment from the Perceptive investment platform, reinforcing conviction in Neurosterix's early-stage pipeline. Acorn Bioventures adds a specialist bioventures perspective to the syndicate.
What does Neurosterix do?
Neurosterix is a biopharmaceutical company headquartered in Geneva, Switzerland, focused on developing allosteric modulators for neuropsychiatric and neurological disorders. Its pipeline includes an M4 positive allosteric modulator (PAM) targeting schizophrenia, an mGlu7 negative allosteric modulator (NAM) for mood disorders, and an mGlu2 NAM aimed at cognitive impairment. The company was founded in 2024 and launched with this Series A financing to advance those therapeutic programmes. Tim Dyer serves as Chief Executive Officer.
Neurosterix valuation & multiples
No existing multiples analysis was provided for this deal. Because Neurosterix's valuation remains undisclosed, EV-based multiples cannot be calculated at this stage. Readers seeking relevant sector benchmarks for biopharmaceutical and neuropsychiatric drug-development companies are invited to explore the sector multiples pages on DealMatrix.
Explore the benchmarks: Series A.
Frequently asked questions
How much did Neurosterix raise in its Series A?
Neurosterix raised USD 63 million in its Series A round, recognised in April 2024.
What is Neurosterix's valuation?
Neurosterix's valuation was not disclosed in connection with this Series A financing.
Who invested in Neurosterix?
The Series A was funded by Perceptive Life Sciences, Perceptive Advisors, and Acorn Bioventures.
When was Neurosterix founded and where is it based?
Neurosterix was founded in 2024 and is headquartered in Geneva, Switzerland.